Abstract
Tolerability to gemcitabine radiochemotherapy was evaluated in 33 patients with inoperable, locally advanced transitional-cell bladder cancers. The dose of 75 mg/m(2) gemcitabine once a week, concurrently with standard radiotherapy of 60 Gy/6 weeks, was found to be acceptable. Eighty-one percentage of 3-year local progression-free survival suggests efficiency warranting further studies.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Carcinoma, Transitional Cell / mortality
-
Carcinoma, Transitional Cell / pathology
-
Carcinoma, Transitional Cell / therapy*
-
Chemoradiotherapy* / adverse effects
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Disease-Free Survival
-
Female
-
Gemcitabine
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Invasiveness
-
Urinary Bladder Neoplasms / mortality
-
Urinary Bladder Neoplasms / pathology
-
Urinary Bladder Neoplasms / therapy*
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Gemcitabine